Scientific Sessions 2025  /  Cardiometabolic Interventions for the Vulnerable Plaque and Vulnerable Patient  /  Targets, Tools, and Tailored Therapy: What's New and What's Next in Lipid Management for Coronary Atherosclerosis
Logo

American Heart Association

  33
  0

Final ID:

Targets, Tools, and Tailored Therapy: What's New and What's Next in Lipid Management for Coronary Atherosclerosis

  • Ballantyne, Christie  ( BAYLOR COLLEGE MEDICINE , Houston , Texas , United States )
    • Author Disclosures:
    Christie Ballantyne: DO have relevant financial relationships ; Researcher:merck:Active (exists now) ; Consultant:Novo Nordisk:Active (exists now) ; Researcher:Novo Nordisk:Active (exists now) ; Consultant:Arrowhead:Active (exists now) ; Researcher:Arrowhead:Active (exists now) ; Consultant:Ionis:Active (exists now) ; Researcher:Ionis:Active (exists now) ; Consultant:Amgen:Active (exists now) ; Researcher:Amgen:Active (exists now) ; Consultant:Eli Lilly:Active (exists now) ; Researcher:Eli Lilly:Active (exists now) ; Consultant:Novartis:Active (exists now) ; Researcher:Novartis:Active (exists now) ; Consultant:Merck:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Cardiometabolic Interventions for the Vulnerable Plaque and Vulnerable Patient

Sunday, 11/09/2025 , 09:45AM - 11:00AM

Cardiovascular Seminar

More abstracts on this topic:
Implications of GLP1 Agonism for Atherosclerosis Disease Progression

Lincoff Abraham, Packer Milton

Imaging Atherosclerosis to Study Disease, Understand Patients and Guide Therapy

Narula Jagat, Maehara Akiko

More abstracts from these authors:
Will apoCIII therapies tip the BALANCE towards targeting triglycerides?

Tsimikas Sotirios, Ballantyne Christie

The Next Era in Cardiometabolic Treatment

Ballantyne Christie

You have to be authorized to contact abstract author. Please, Login
Not Available